Related to Novartis Signs Four-Year Deal with Horizon for Custom-Generated X-Man Cancer Models

• Novartis Acquires Opexa’s Stem Cell Technology for $4M
  
• Novartis to Further Orexo’s Mid-Stage GERD Treatment
  
• BTG Sells Drug Delivery Platform to Novartis
  
• Novartis Nabs Global Commercialization Rights to Paratek's Late-Stage Antibiotic
  
• Novartis Shells Out $200M for U.S. and Canadian Rights to Vanda’s FDA-Approved Schizophrenia Drug
  
• Human Genome Sciences Earns $75M from Novartis as HCV Drug Gets Prepared for Regulatory Submissions
  
• Novartis Shells Out $210M for Two of Incyte’s Hematology-Oncology Candidates
  
• Horizon Negotiates Licenses to Gene Engineering Technology from University of Washington
  
• BioMimetic Strengthens Arrangement with Novartis for Exclusive Supply of Recombinant Human Platelet-Derived Growth Factor
  
• Novartis Pays Proteus $24M as Part of Sensor-Based Organ-Transplant Product Partnership
  
• Novartis Gains GenVec’s Preclinical Hearing-Loss and Balance-Disorder Program for $5M
  
• Novartis Nabs Imperial College’s Preclinical Meningitis B Vaccine
  
• Novartis Negotiates Rights to Debiopharm’s Mid-Stage HCV Candidate
  
• Horizon and University of Torino Win $500K Grant to Develop SNP-Based Cancer Models
  
• Novartis to Evaluate NasVax Adjuvant Technology
  

• Novartis to Exploit Nuevolution Platform for Drug Discovery

  
  
• Vectura Bags $7.5M as Novartis Starts Phase III Development of COPD Therapy
  
• Interim Analysis of Novartis’ Osteoarthritis Therapy Suggests Lack of Efficacy Benefit
  
• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA